Inovio Pharmaceuticals, Inc.
INO
$2.05
$0.105.13%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -44.19% | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -44.19% | -- | |||
| Cost of Revenue | 24.88% | -31.22% | |||
| Gross Profit | -25.51% | 31.84% | |||
| SG&A Expenses | 18.73% | -11.76% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 22.60% | -25.09% | |||
| Operating Income | -22.98% | 25.52% | |||
| Income Before Tax | -1.61% | 22.98% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -1.61% | 22.98% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -1.61% | 22.98% | |||
| EBIT | -22.98% | 25.52% | |||
| EBITDA | -23.69% | 25.90% | |||
| EPS Basic | 21.08% | 27.74% | |||
| Normalized Basic EPS | 19.10% | 31.04% | |||
| EPS Diluted | 21.08% | 27.74% | |||
| Normalized Diluted EPS | 19.10% | 31.04% | |||
| Average Basic Shares Outstanding | 28.74% | 6.58% | |||
| Average Diluted Shares Outstanding | 28.74% | 6.58% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||